Lumibird SA Stocks

24.05Last Updated 24.04.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

€ 627.55M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
24.05
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Lumibird SA engages in the design, manufacturing and marketing of lasers. The company is headquartered in Lannion, Bretagne and currently employs 541 full-time employees. The firm offers a range of products, including compact pulsed Nd, double-pulse Nd, tunable laser systems, flash-lamp pumped lasers, diode-pumped solid-state lasers, semiconductor laser modules and intense pulsed light instruments, among others. Lumibird provides lasers to industrial and scientific clients, as well as the medical sector, among others. The firm operates worldwide through the subsidiaries, such as Quantel Medical, which specializes in the development and marketing of diagnostic ocular ultrasound systems and surgical lasers; Quantel USA, which designs and produces fiber lasers, glass laser systems and tunable lasers, and Quantel Derma AT, which focuses on the development, production and sales of the laser technology products in the areas of dermatology and aesthetics.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks